Skip to main navigation
Skip to Content
logo
  • Overview
  • News & Events
    • News Releases
    • Events
    • Presentations
  • Corporate Governance
    • Documents & Charters
    • Management Team
    • Board of Directors
    • Committee Composition
  • Financials & Filings
    • SEC Filings
    • Quarterly Results
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • IR Resources
    • FAQs
    • Email Alerts
    • Contact IR

Committee Composition

Independent Director Audit Committee Compensation Committee Nominating and Corporate Governance Committee
James E. Cashman III Independent Director Compensation Committee Nominating and Corporate Governance Committee
Eran Broshy Independent Director Audit Committee Nominating and Corporate Governance Committee
Cynthia Collins Independent Director Audit Committee
Rosemary Crane Independent Director Compensation Committee
Nancy Killefer Independent Director Compensation Committee Nominating and Corporate Governance Committee
Stephen McLean Independent Director Nominating and Corporate Governance Committee
David Spaight Independent Director Compensation Committee
Matthew Walsh Independent Director Audit Committee
= Independent Director = Chairperson = Member

  

- Certara - Investor Tools

Print Page
Email Alerts
RSS
FAQs
Contact IR
Certara Logo

Services

  • Services
  • Cell and Gene Therapy
  • Clinical Pharmacology
  • Complex Biologics
  • Decision Analytics and Modeling
  • Drug Development and Regulatory Strategy
  • French SNDS Data Access and Analysis
  • Health Economics Outcomes Research
  • Market Access and Pricing
  • Medical and Regulatory Communications
  • Model-based Meta Analysis
  • Oligonucleotide – Complex Biologics
  • Pediatric Practice
  • Pharmacometrics
  • Phoenix Technology Services
  • Pre Clinical / IND Enabling Services
  • Quantitative Systems Pharmacology
  • Quantitative Systems Toxicology and Safety
  • Real World Evidence
  • Regulatory Affairs and Submission Strategy
  • Regulatory Operations
  • Regulatory Technology
  • Safety and Pharmacovigilance
  • Simcyp PBPK Modeling
  • Therapeutic Areas
  • Transparency and Disclosure
  • US and EU Payer Engagement
  • US Managed Markets
  • Value Strategy
  • Virtual Bioequivalence

Software

  • Software
  • PHOENIX™ PK/PD PLATFORM v 8.3 NEW
  • Phoenix WinNonlin
  • Phoenix NLME
  • Phoenix IVIVC Toolkit
  • SIMCYP™ PBPK SIMULATOR
  • Simcyp Animal
  • Simcyp Pediatric
  • Quantitative Systems Pharmacology
  • Quantitative Systems Toxicology and Safety
  • D360 Scientific Informatics Platform
  • Integral Data Repository
  • BaseCase Value Communication Software
  • Simcyp Cardiac Safety Simulator
  • CODEx & Clinical Trial Outcomes Databases
  • D360 Express
  • GlobalSubmit eCTD Submissions Software
  • Health Outcomes Performance Estimator (HOPE)
  • Phoenix NLME Validation Suite
  • Phoenix WinNonlin Validation Suite
  • Pirana Modeling Workbench
  • PKAssist
  • PK Submit CDISC Technology Solution
  • Preclinical Safety Store
  • Simcyp In Vitro Data Analysis Toolkit (SIVA)
  • Trial Simulator

Resources

  • Resources
  • 4A Decision Framework
  • Articles
  • Blogs
  • BIO Europe 2020
  • BIO 2020
  • Case Studies
  • Certara in the Press
  • Certara University
  • Certification Program
  • Conferences
  • COVID-19 Resource Hub
  • COVID-19 Scientific Webinar Series
  • Disruptive Trends in U.S. Market Access
  • Knowledge Base
  • PML School
  • Podcasts
  • Publications
  • Simcyp Workshops
  • Support
  • Virtual Patients
  • Webinars
  • White Papers

Company

  • Company
  • Careers
  • Certara Code of Conduct
  • Contact Certara
  • Leadership
  • Legal
  • Locations
  • News
  • Our Story
  • Partners
  • Privacy Center
  • The Simcyp Consortium
  • Privacy Center
  • Legal

Subscribe for updates

 
Please find the Certara privacy policy here. You can unsubscribe, and withdraw your consent, at any time.
LinkedIn Blog Youtube Twitter Facebook